Literature DB >> 24338436

Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns.

Cathal P O'Brien1, Stephen E Langabeer, Kenneth J O'Byrne, John J O'Leary, Stephen P Finn.   

Abstract

Mesh：

Year:  2014        PMID： 24338436     DOI： 10.1007/s40291-013-0076-x

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


× No keyword cloud information.
  15 in total

1.  BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.

Authors:  Hao-Wei Teng; Yu-Chung Huang; Jen-Kou Lin; Wei-Shone Chen; Tzu-Chen Lin; Jeng-Kai Jiang; Chueh-Chuan Yen; Anna Fen-Yau Li; Hsei-Wei Wang; Shih-Ching Chang; Yuan-Tzu Lan; Chun-Chi Lin; Huann-Sheng Wang; Shung-Haur Yang
Journal:  J Surg Oncol       Date:  2012-02-13       Impact factor: 3.454

2.  Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

Authors:  Cecily P Vaughn; Scott D Zobell; Larissa V Furtado; Christine L Baker; Wade S Samowitz
Journal:  Genes Chromosomes Cancer       Date:  2011-02-08       Impact factor: 5.006

3.  Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Authors:  Jolien Tol; Jeroen R Dijkstra; Marjolein Klomp; Steven Teerenstra; Martin Dommerholt; M Elisa Vink-Börger; Patricia H van Cleef; J Han van Krieken; Cornelis J A Punt; Iris D Nagtegaal
Journal:  Eur J Cancer       Date:  2010-04-21       Impact factor: 9.162

4.  The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Authors:  Silvy da Rocha Dias; Tomas Salmonson; Barbara van Zwieten-Boot; Bertil Jonsson; Serena Marchetti; Jan H M Schellens; Rosa Giuliani; Francesco Pignatti
Journal:  Eur J Cancer       Date:  2013-03-05       Impact factor: 9.162

5.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Authors:  Susan D Richman; Matthew T Seymour; Philip Chambers; Faye Elliott; Catherine L Daly; Angela M Meade; Graham Taylor; Jennifer H Barrett; Philip Quirke
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

6.  Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.

Authors:  Masaru Shinozaki; Akihide Fujimoto; Donald L Morton; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.

Authors:  Emma Borràs; Ismael Jurado; Imma Hernan; María José Gamundi; Miguel Dias; Isabel Martí; Begoña Mañé; Angels Arcusa; José A G Agúndez; Miguel Blanca; Miguel Carballo
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

9.  Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

Authors:  Molly Yancovitz; Adam Litterman; Joanne Yoon; Elise Ng; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Farbod Darvishian; Paul Christos; Madhu Mazumdar; Iman Osman; David Polsky
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

10.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.